Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsXtalPi announced Kodexia on October 6, 2026, as a proprietary platform that combines AI-driven small interfering RNA (siRNA) design with automated laboratory experiments and feedback from experimental results. The company also reported six preclinical programs, including an IgA nephropathy program with non-human-primate efficacy data. Those capabilities and results are company-reported; the announcement does not provide independent validation.
What Kodexia is—and what it is not
Kodexia is XtalPi’s research platform for discovering and optimizing siRNA candidates. It is not a consumer-facing AI tool or an approved medicine. The six programs announced alongside it are preclinical assets, meaning the disclosed work is at the research stage rather than evidence of safety or efficacy in people.
As an Amazon Associate I earn from qualifying purchases.
siRNA molecules are designed to reduce the expression of a selected gene by engaging the cell’s RNA-interference machinery. Designing a candidate therefore involves more than finding a sequence that matches a target: researchers must also consider how the molecule behaves, whether it reaches the relevant tissue, and whether it silences the intended target without unacceptable unintended effects. XtalPi presents Kodexia as a system intended to address these linked design and testing problems.
How XtalPi describes the closed loop
The platform’s stated workflow connects computational design with automated experiments. Experimental outcomes are fed back into the models so subsequent design rounds can use empirical results, rather than treating sequence generation and laboratory validation as separate stages.
#1 Best Overall
- Identify target regions. XtalPi says AI is used to explore target regions and assess their suitability for siRNA design.
- Generate sequences and recommend chemical modifications. The company describes sequence design and modification selection as integrated parts of the workflow, rather than independent steps.
- Test candidates. Automated laboratory experiments assess the designed molecules, with XtalPi reporting both in vitro and in vivo experimental activity.
- Feed results back into design. Experimental outcomes inform further model iterations and candidate optimization.
- Consider delivery and intellectual property. XtalPi’s product-page description extends the workflow to delivery optimization and intellectual-property planning.
This general loop is not entirely new to the public description of Kodexia: XtalPi’s 2025 annual-report disclosure, filed in April 2026, had already described an AI-powered siRNA sequence and chemical-modification platform with iterative functional validation. The October 2026 announcement expands the public account with platform and pipeline claims.
What siFormer is intended to contribute
XtalPi identifies siFormer as Kodexia’s core architecture. The company says it incorporates RNA-interference biology and nucleic-acid chemistry, including RNA thermodynamics and structural features relevant to strand loading, target accessibility, and gene silencing. In XtalPi’s account, these constraints are used to steer generation toward designs that are biologically plausible, rather than simply producing sequences that match a target computationally.
The stated optimization objective is multi-dimensional. XtalPi says the system considers potency, performance in vivo, durability, off-target activity, safety, and patentability. These are design goals, not evidence that every candidate—or the platform as a whole—has achieved those outcomes. A candidate can perform well on one dimension while requiring compromises or further testing on another.
Additional design and delivery areas
XtalPi’s product page says the platform’s research includes dual-target siRNA and delivery approaches intended to extend beyond conventional applications. The delivery work it describes includes antibody, peptide, and small-molecule conjugates, as well as lipid nanoparticles. The sources describe these as areas of platform work; they do not establish that each approach is clinically validated or used in every announced program.
The company’s April 2026 annual-report disclosure had also identified extrahepatic delivery and dual-target siRNA as areas under exploration. That context matters because delivery to tissues beyond the liver remains a design challenge for RNA medicines, but the disclosed platform materials do not provide a comparative demonstration that Kodexia has solved it.
What XtalPi reported about throughput and performance
The figures below are claims made by XtalPi in its October 6, 2026 announcement. The available material does not establish them through independent testing or a published head-to-head comparison.
| Claim | What XtalPi reported | How to interpret it |
|---|---|---|
| Experimental throughput | More than 500 in vitro experiments and 30 in vivo experiments weekly. | A company-reported weekly operating figure; the announcement does not provide an independent audit or enough methodological detail to compare it directly with another laboratory. |
| Design efficiency | Nearly a threefold increase in molecular design efficiency compared with conventional workflows. | XtalPi’s comparison. The announcement does not establish an independently measured benchmark or define a universal conventional-workflow baseline. |
| First-round activity | More than 50% of first-round designs tested across multiple programs reportedly showed stronger in vivo activity than positive controls. | A company-reported result across multiple programs, not a general hit rate for all Kodexia designs. The announcement does not supply independent validation. |
Six preclinical programs and the IgA nephropathy update
XtalPi said it had six proprietary programs across metabolic, renal, respiratory, and central nervous system diseases, with more than half having completed in vivo efficacy evaluations. These are preclinical development updates from the company; they do not imply that the programs have entered clinical trials.
The highlighted lead program targets immunoglobulin A (IgA) nephropathy, a kidney disease. XtalPi reported non-human-primate efficacy data within seven months and said candidate selection was on track within a nine-month project timeline. It compared that timeline with a company-stated industry norm of 12 to 18 months. The comparison is XtalPi’s, and the announcement does not provide independent evidence that this is a standardized industry benchmark or that the timing predicts clinical success.
Best Value
XtalPi characterized the IgA program as an early empirical validation of its integrated platform. Non-human-primate data can inform preclinical assessment, but it is not human clinical evidence and does not establish that a treatment is safe or effective for patients.
What the announcement does—and does not—establish
The October 6, 2026 announcement is evidence of what XtalPi says Kodexia does and what the company reports about its programs. The figures for design efficiency, in vivo activity, throughput, and the lead program’s timeline are not independently confirmed in the materials described here. The sources also do not establish an independent head-to-head ranking of Kodexia against other siRNA discovery platforms.
For biotech and pharmaceutical organizations, XtalPi’s official product page says the company welcomes strategic collaboration, licensing, and asset co-development. That is an invitation stated by the company, not confirmation of any particular deal, program availability, or collaboration terms.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
